GSK said it decided to halt the development of an experimental drug as a treatment for chronic cough after the Medicine missed the key goal
GSK said it decided to halt the development of an experimental drug as a treatment for chronic cough after the Medicine missed the key goal in a late-stage clinical study; said the drug, camlipixant, achieved mixed results in two trials--with one hitting the primary objective of significant reductions in cough frequency after 12 weeks of treatment and a second falling short after 24 weeks; shares -4.3% premarket
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.